Sarvari Yellapragada, MD

Peer-Reviewed Articles

1. Patel N, Al Hadidi S, Yellapragada S. Pathophysiology and Treatments of Complications of Waldenström's Macroglobulinemia. Clin Hematol Int 6(4):11-18, 2024. PMID: 39417016.
2. Inchaustegui C, Yellapragada S, Badawy J, Ahmed A, White A, Sargsyan Z. Dyspneic and pink. J Hosp Med 19(7):623-628, 2024. e-Pub 2024. PMID: 38563412.
3. Nguyen TM, Amenta E, Chapman L, Yellapragada S, Krishnan B, Lim J, Hamill RJ. Ibrutinib-associated cutaneous mucormycosis due to an Apophysomyces species: report of a case and review of the literature. Ther Adv Infect Dis 11, 2024. e-Pub 2024. PMID: 38545450.
4. Patel, N, Al-Hadidi, SA, Yellapragada, SV. PATHOPHYSIOLOGY AND TREATMENTS OF COMPLICATIONS OF WALDENSTRÖM’S MACROGLOBULINEMIA. Clinical Hematology International 6(4):11-18, 2024. e-Pub 2024. PMID: 39417016.
5. Cay G, Sada YH, Dehghan Rouzi M, Uddin Atique MM, Rodriguez N, Azarian M, Finco MG, Yellapragada S, Najafi B. Harnessing physical activity monitoring and digital biomarkers of frailty from pendant based wearables to predict chemotherapy resilience in veterans with cancer. J Rural Health 14(1):2612, 2024. e-Pub 2024. PMID: 38297103.
6. Friedman DR, Rodgers TD, Kovalick C, Yellapragada S, Szumita L, Weiss ES. Veterans with blood cancers: Clinical trial navigation and the challenge of rurality. J Rural Health 40(1):114-120, 2024. e-Pub 2024. PMID: 37389421.
7. Jang, A, Jang, A, Hamad, H, Hamad, H, Teegarapavu, S, Teegarapavu, S, Yellapragada, SV, Yellapragada, SV, Rivero, GA, Rivero, GA. Inferior Survival Among Polycythemia Vera Patients Exhibiting Body Mass Index Reduction. SN Comprehensive Clinical Medicine 5(1), 2023. e-Pub 2023.
8. Lurain K, Zarif TE, Ramaswami R, Nassar AH, Adib E, Abdel-Wahab N, Chintapally N, Drolen CE, Feldman T, Haykal T, Nebhan CA, Kambhampati S, Li M, Mittra A, Lorentsen M, Kim C, Drakaki A, Morse M, Johnson DB, Mangla A, Dittus C, Ravi P, Baiocchi RA, Chiao EY, Rubinstein PG, Yellapragada SV, LaCasce AS, Sonpavde GP, Naqash AR, Herrera AF. Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States. Clin Lymphoma Myeloma Leuk 24(8):523-530, 2023. PMID: 38714474.
9. Yellapragada S, Iakova P, Moree SE, Hsu JI, Mistry RM, Stossi F, Lulla P, Sun Z, Sahin E, Yellapragada SV, Catic A. Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 (HDAC3) Stabilization and Chromatin Condensation. Cancer Res Commun 2(12):1693-1710, 2022. PMID: 36846090.
10. Khan S, Alam ST, Ramos RT, Mbue JE, Apostolidou E, Rivero GA, Yellapragada SV. Luspatercept in Low-Risk Myelodysplastic Syndrome: A Real-World Single Institution Case Series. Clin Hematol Int 4(4):148-151, 2022. PMID: 35997953.
11. Alam ST, Dongarwar D, Lopez E, Yellapragada S, Rivero G, Huang Q, Miler-Chism C, Mims M, Salihu HM. Disparities in mortality among acute myeloid leukemia-related hospitalizations. Cancer Med 12(3):3387-3394, 2022. e-Pub 2022. PMID: 35924430.
12. Khan S, Premji S, Huang Q, Verstovsek G, Bushan S, Yellapragada SV. An eye‐catching atypical illustration of the evaluation and management of AL amyloidosis secondary to myeloma. Clin Case Rep 9(12):e05176, 2021. PMID: 34938552.
13. Fillmore NR, Cirstea D, Munjuluri A, Yameen H, Yellapragada SV, Do NV, Brophy MT, Szalat RE, Munshi NC. Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study. Blood Adv 5(18):3511-3514, 2021. PMID: 34428278.
14. Al Hadidi S, Yellapragada S. Treatment Options for Relapsed and Refractory Multiple Myeloma: A Luxury or a Challenge?. JAMA Oncol 7(10):1449-1450, 2021. PMID: 34383000.
15. Kang GE, Murphy TK, Kunik ME, Badr HJ, Workeneh BT, Yellapragada SV, Sada YH, Najafi B. The detrimental association between fear of falling and motor performance in older cancer patients with chemotherapy-induced peripheral neuropathy. Gait Posture 88:161-166, 2021. PMID: 34091147.
16. DuMontier C, Fillmore NR, Yildirim C, Cheng D, La J, Orkaby AR, Charest B, Cirstea D, Yellapragada S, Gaziano JM, Do N, Brophy MT, Kim DH, Munshi NC, Driver JA. Contemporary Analysis of Electronic Frailty Measurement in Older Adults with Multiple Myeloma Treated in the National US Veterans Affairs Healthcare System. Cancers (Basel) 13(12):3053, 2021. PMID: 34207459.
17. DuMontier C, La J, Bihn J, Corrigan J, Yildirim C, Dharne M, Hassan H, Yellapragada S, Abel GA, Gaziano JM, Do NV, Brophy M, Kim DH, Munshi NC, Fillmore NR, Driver JA. Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database. Blood Adv 193(3):532-541, 2021. e-Pub 2021. PMID: 37582048.
18. Maneix L, Sweeney MA, Lee S, Iakova P, Moree SE, Sahin E, Lulla P, Yellapragada SV, Tsai FTF, Catic A. The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma. Cancers (Basel) 13(4):843, 2021. PMID: 33671345.
19. Nguyen CB, Li M, Verstovsek G, Sen U, Swierenga C, Huang Q, Rivero G, Yellapragada SV. Primary bone lymphoma of the ilium successfully treated without radiation. Clin Case Rep 8(12):3129-3132, 2020. PMID: 33363894.
20. Yellapragada SV, Fillmore NR, Frolov A, Zhou Y, Dev P, Yameen H, Ifeorah C, Do NV, Brophy MT, Munshi NC. Vitamin D deficiency predicts for poor overall survival in white but not African American patients with multiple myeloma. Blood Adv 4(8):1643-1646, 2020. PMID: 32315398.
21. Fillmore NR, Yellapragada SV, Ifeorah C, Mehta A, Cirstea D, White PS, Rivero G, Zimolzak A, Pyarajan S, Do N, Brophy M, Munshi NC. With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study. Blood Adv 133(24):2615-2618, 2019. PMID: 31003998.
22. Zahiri M, Chen KM, Zhou H, Nguyen H, Workeneh BT, Yellapragada SV, Sada YH, Schwenk M, Najafi B. Using wearables to screen motor performance deterioration because of cancer and Chemotherapy-Induced Peripheral Neuropathy (CIPN) in adults- Toward an early diagnosis of CIPN 10(6):960-967, 2019. PMID: 30665876.
23. Chang E, Sabichi AL, Kramer JR, Hartman C, Royse KE, White DL, Patel NR, Richardson P, Yellapragada SV, Garcia JM, Chiao EY. Nivolumab Treatment for Cancers in the HIV-infected Population. J Immunother 19(12):3223-3232, 2018. PMID: 30020193.
24. Chang E, Rivero G, Patel NR, Chiao EY, Lai S, Bajaj K, Mbue JE, Yellapragada SV. HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab. Clin Lymphoma Myeloma Leuk 18(2):e143-e146, 2018. PMID: 29342442.
25. Li A, Yellapragada SV, Mims M, Frolov A, Rivero GA. Significant improvement in overall survival among patients diagnosed with low-risk myelodysplastic syndrome treated with selective serotonin reuptake inhibitors. Br J Haematol, 2017. PMID: 27061100.
26. Chang E, Rivero G, Jiang B, Yellapragada S, Thiagarajan P. Gelatinous Marrow Transformation Associated with Imatinib: Case Report and Literature Review. Case Rep Hematol 2017:1950724, 2017. e-Pub 2017. PMID: 28133556.
27. Amini B, Yellapragada S, Shah S, Rohren E, Vikram R. State-of-the-Art Imaging and Staging of Plasma Cell Dyscrasias. Radiol Clin North Am 54(3):581-96, 2016. PMID: 27153790.
28. Molina M, Yellapragada S, Mims M, Rahman E, Rivero G. Pulmonary Complications of Azanucleoside Therapy in Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia. Case Rep Hematol 2015(1):357461, 2015. PMID: 26798526.
29. Girnius SK, Lee S, Kambhampati S, Rose MG, Mohiuddin A, Houranieh A, Zimelman A, Grady T, Mehta P, Behler C, Hayes TG, Efebera YA, Prabhala RH, Han A, Yellapragada SV, Klein CE, Roodman GD, Lichtenstein A, Munshi NC. . A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation. Br J Haematol 169(1):36-43, 2015. PMID: 25572917.
30. Khalid U, Awar O, Verstovsek G, Cheong B, Yellapragada SV, Jneid H, Deswal A, Virani SS. Case report: isolated cardiac amyloidosis: an enigma unravelled. Case report: Methodist Debakey Cardiovasc J 11(1):53-8, 2015. PMID: 25793032.
31. Nautiyal K, Li R, Yellapragada S, Thiagarajan P, Mims M, Rivero G. Progressive transfusion and growth factor independence with adjuvant sertraline in low risk myelodysplastic syndrome treated with an erythropoiesis stimulating agent and granulocyte-colony stimulating factor. Leuk Res Rep 4(1):1-3, 2014. PMID: 25709889.
32. Albany C, Alva AS, Aparicio AM, Singal R, Yellapragada S, Sonpavde G, Hahn NM. Epigenetics in prostate cancer. Prostate Cancer, 2011. PMID: 22191037.
33. Alva AS, Hahn NM, Aparicio AM, Singal R, Yellapragada S, Sonpavde G. Hypomethylating agents for urologic cancers, 2011. PMID: 21417907.
34. Guchhait P, Dasgupta SK, Le A, Yellapragada S, López JA, Thiagarajan P. Lactadherin mediates sickle cell adhesion to vascular endothelial cells in flowing blood. Haematologica 92(9):1266-7, 2007. PMID: 17768123.

Review Articles

1. Ekpenyong, E, Mohsin, M, Al-Hadidi, SA, Yellapragada, SV. Access to Bispecific Therapies for Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia 26(7):e885-e892, 2026. e-Pub 2026. PMID: 42135142.
2. Hussain M, Yellapragada S, Al Hadidi S. Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article. Blood Lymphat Cancer 13:33-57, 2023. PMID: 37731771.

Other Articles

1. Lurain K, El Zarif T, Ramaswami R, Nassar AH, Adib E, Abdel-Wahab N, Chintapally N, Drolen CE, Feldman T, Haykal T, Nebhan CA, Kambhampati S, Li M, Mittra A, Lorentsen M, Kim C, Drakaki A, Morse M, Johnson DB, Mangla A, Dittus C, Ravi P, Baiocchi RA, Chiao EY, Rubinstein PG, Yellapragada SV, LaCasce AS, Sonpavde GP, Naqash AR, Herrera AF Corrigendum to 'Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States' [Clinical Lymphoma, Myeloma, and Leukemia Volume 24, Issue 8, August 2024, Pages 523-530]. Clin Lymphoma Myeloma Leuk 24(12):873, 2024. PMID: 39603773.
2. Fillmore NR, DuMontier C, Yildirim C, La J, Epstein MM, Cheng D, Cirstea D, Yellapragada S, Abel GA, Gaziano JM, Do N, Brophy M, Kim DH, Munshi NC, Driver JA Defining Multimorbidity and Its Impact in Older United States Veterans Newly Treated for Multiple Myeloma. J Natl Cancer Inst 113(8):1084-1093, 2021. PMID: 33523236.

Abstracts

1. Krem MM, Corrigan JK, Yellapragada S, Bennett JG, Do NV, Brophy MT, Munshi NC, Friedman DR, Fillmore NR. RVD With Weekly Bortezomib Has a Favorable Toxicity and Effectiveness Profile in a Large Cohort of US Veterans With Multiple Myeloma. AVAHO 41(9):s33, 2024. e-Pub 2024.
2. Ramos RT, Rajan R, Sengsayadeth S, Dunn D, Sawyer J, Shultes K, Williams R, Gremillion R, Nguyen T, Yellapragada S. The First Female Patient in the Veteran Affairs System to Receive Chimeric Antigen Receptors (CAR) T-cell Therapy for Refractory Multiple Myeloma and the Role of CAR T-cell Therapy in Penta-refractory Disease. AVAHO, 2024. e-Pub 2024.
3. Kirby C, Atweh G, Rosko AE, Friedman DR, Yellapragada S, Vashistha V. Clinicopathologic features and outcomes associated with induction regimen intensity among older veterans with myeloma. 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
4. Jang A, Hamad H, Teegarapavu S, Yellapragada SV, Rivero GA. Inferior Survival Among Polycythemia Vera Patients Exhibiting Body Mass Index Reduction 5(120), 2023. e-Pub 2023.
5. Sen Aditi A, Nidhi A, Sarvari Y, Mbue John E, Maulin S. Novel Treatment Option for PLA2R-Positive Membranous Nephropathy 33(11S):506, 2022. e-Pub 2022.
6. Jang A, Hamad H, Teegarapavu S, Yellapragada S, Rivero G. Inferior Survival Among Polycythemia Vera Patients Exhibiting Body Mass Index Reduction 1, 2022. e-Pub 2022.
7. Catic A, Maneix L, Iakova P, Mistry R, Stossi F, Yellapragada S, Lulla P. Epigenetic Silencing of MYC By Proteasome Inhibitors. ASH 2021 138(1):2212, 2021. e-Pub 2021.
8. Premji S, Yildirim C, Fillmore N, Yellapragada S, Brophy M, Do N, Huang Q, Friedman D, Munshi N. Second primary malignancies (SPM) in African American (AA) and white patients with multiple myeloma in the National Veterans Affairs (VA) healthcare system. ASCO Annual Meeting 2021 39(15), 2021. e-Pub 2021.
9. Romero J, Mazzini J, Yellapragada SV, Sosa IR, Rivero GA. Elderly Hemopoietic and Inflammatory Signature for Life-Threatening COVID-19 Infection. ASH 2020 136(1):36-37, 2020. e-Pub 2020.
10. Yellapragada S, Frolov A, Fillmore N, Dev P, Shafi Ifeorah C, Do N, Munshi N. Vitamin D deficiency predicts for poor overall survival in white but not African American patients with multiple myeloma. ASH Annual Meeting 2018 4(8):1643-1646, 2020. e-Pub 2020.
11. Fillmore N, Yellapragada S, Yildirim C, Afrough A, Attanathi A, Chizoba I, Do N, Brophy M, Munshi N. Incidence of Second Primary Malignancies and Association with Treatment in US Veterans with Multiple Myeloma. ASH Annual Meeting 2019 134(1):1806, 2019. e-Pub 2019.
12. Munjuluri A, Fillmore N, Cirstea D, Yameen H, Yellapragada S, Ifeorah C, Do N, Brophy M, Munshi N. With Equal Access, African Americans with Non-del17p Multiple Myeloma Have Superior Overall Survival, but del17p Still Carries Poor Prognosis across Race: A VA Study. ASH Annual Meeting 2019 134(1):4388, 2019. e-Pub 2019.
13. Talukder R, Yellapragada S, Hussein H, Rivero G. Predictive Factors for Complete Remission and Survival in AML Patients Failing to Achieve Adequate Bone Marrow Day 14 Blast Eradication. ASH Annual Meeting 2018 132(1):1464, 2018. e-Pub 2018.
14. Fillmore N, Yellapragada S, Ifeorah C, Do N, Munshi M. With Equal Access and Utilization of Resources,Younger African American Patients Have Superior Survival Compared to Caucasian Patients Diagnosed with Multiple Myeloma at the Veterans Affairs Hospitals. ASH Annual Meeting 2018 132(1):3191, 2018. e-Pub 2018.
15. Yellapragada S, Ifeorah C, Fletcher L, Rivero G, Yasin Z, Krieger J, Mulchandani A, Catic A, Mims MP. Differential response to carfilzomib based on initial therapy with bortezomib in multiple myeloma. ASCO Annual Meeting 2017, 2017. e-Pub 2017.
16. Rodriguez C, Pedro A, Yellapragada S, Mims MP, Rivero G. Traceable Red Cell Distribution Width Modifications Are Observed Prior to MDS Diagnosis and Primarily Associated with Cardiovascular Organ Dysfunction. ASH Annual Meeting 2016 128(22):5537, 2016. e-Pub 2016.
17. Ventura M, Bernard D, Taveras Alam S, Schlichte M, Krishnan B, Thiagarajan P, Rivero G, Vasudevan M, Yellapragada S. Treatment of acquired factor VIII inhibitor in the setting of bullous pemphigoid. SGIM 2019.
18. Arnell M, Williams R, Vaclavik L, Rivero G, Horstman M, Yellapragada S. Improving patient navigation and time to hematopoietic stem cell transplant. SHM 2020.
19. Swierenga YA, Mbue J, Yellapragada, S. BCMA:The Ultimate Target in Plasma Cell Neoplasms Authors. BCM: Housestaff Symposium 2023.
20. Lu J, Yellapragada S. Persistent Leukocytosis; A Rare Case of Chronic Neutrophilic Leukemia. BCM: Housestaff Symposium 2023.
21. Nguyen T, Swierenga C, Chinratanalab W, Cernawsky S, Sawyer J, Rhonda Williams KS, Mbue J, Yellapragada S. The First Patient in the Veteran Affairs System to Receive Chimeric Antigen Receptors T-cell Therapy for Refractory Multiple Myeloma and the Role of Intravenous Immunoglobulin in the Prevention of Therapy-associated Infection. AVAHO 41(suppl 4):S20-S21.
22. Tannenbaum D, Nguyen T, Raynaldo G, Hamad H, London D, Balchandani R, Rivero G, Yellapragada S. The Light Chain Escape Phenomenon in Multiple Myeloma. SHM 2017.
23. Tannenbaum D, Nguyen T, Raynaldo G, Hamad H, London D, Balchandani R, Rivero G, Yellapragada S. The Light Chain Escape Phenomenon in Multiple Myeloma. SGIM 2017.

Book Chapters

1. Yellapragada SV, Bergstrom KL. Hematological disorders. In: Handbook of Clinical Adult Genetics and Genomics. Academic Press, 213-230, 2020.
2. Huang Q, Cannon N, Teegavarapu S, Yellapragada S. Myeloid Disorders. In: Handbook of Benign Hematology. Springer Publishing Company, 49-47, 2019.
3. Lulla P, Yellapragada S. Non-Hodgkin’s Lymphoma. In: Tumor board review: guideline and case reviews in oncology. Demos Medical Publishing, 322-336, 2015.
4. Arani M, Yellapragada SV. Acute Myelogenous Leukemia. In: Tumor Board Review: Guideline and Case Reviews in Oncology, 305-326.